share_log

愛帝宮:翌日披露報表

AIDIGONG: Next Day Disclosure Return

HKEX ·  Nov 5, 2024 20:01

Summary by Moomoo AI

愛帝宮母嬰健康股份有限公司(愛帝宮)於2024年11月6日根據香港聯合交易所有限公司證券上市規則披露已發行股份變動。該公司於2024年10月31日的已發行股份為147,833,832股,而在2024年11月6日完成配售新股後,已發行股份增至192,183,832股,增加了44,350,000股,佔增發前已發行股份的30%。新股的配售價格為每股HKD 1.68,該配售是根據2024年6月20日的配售協議及特別授權完成。公司確認所有交易均獲董事會批准,並遵守相關上市規則及法律規定。
愛帝宮母嬰健康股份有限公司(愛帝宮)於2024年11月6日根據香港聯合交易所有限公司證券上市規則披露已發行股份變動。該公司於2024年10月31日的已發行股份為147,833,832股,而在2024年11月6日完成配售新股後,已發行股份增至192,183,832股,增加了44,350,000股,佔增發前已發行股份的30%。新股的配售價格為每股HKD 1.68,該配售是根據2024年6月20日的配售協議及特別授權完成。公司確認所有交易均獲董事會批准,並遵守相關上市規則及法律規定。
Aidigong Maternal and Child Health Co., Ltd. (Aidigong) disclosed changes in issued shares according to the Listing Rules of The Stock Exchange of Hong Kong Limited on November 6, 2024. The company had 147,833,832 issued shares as of October 31, 2024. After completing the placement of new shares on November 6, 2024, the issued shares increased to 192,183,832 shares, an increase of 44,350,000 shares, accounting for 30% of the issued shares before the increase. The placement price of the new shares was HKD 1.68 per share, and the placement was completed in accordance with the placement agreement and special authorization dated June 20, 2024. The company confirmed that all transactions were approved by the board of directors and complied with relevant listing rules and legal requirements.
Aidigong Maternal and Child Health Co., Ltd. (Aidigong) disclosed changes in issued shares according to the Listing Rules of The Stock Exchange of Hong Kong Limited on November 6, 2024. The company had 147,833,832 issued shares as of October 31, 2024. After completing the placement of new shares on November 6, 2024, the issued shares increased to 192,183,832 shares, an increase of 44,350,000 shares, accounting for 30% of the issued shares before the increase. The placement price of the new shares was HKD 1.68 per share, and the placement was completed in accordance with the placement agreement and special authorization dated June 20, 2024. The company confirmed that all transactions were approved by the board of directors and complied with relevant listing rules and legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more